<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Apatinib</id>
	<title>Apatinib - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Apatinib"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Apatinib&amp;action=history"/>
	<updated>2026-04-27T10:12:21Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Apatinib&amp;diff=6293016&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Apatinib&amp;diff=6293016&amp;oldid=prev"/>
		<updated>2025-02-15T10:47:34Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{DISPLAYTITLE:Apatinib}}&lt;br /&gt;
&lt;br /&gt;
== Overview ==&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Apatinib&amp;#039;&amp;#039;&amp;#039; is a small molecule tyrosine kinase inhibitor that selectively targets the vascular endothelial growth factor receptor-2 ([[VEGFR-2]]). It is primarily used in the treatment of various types of cancer, particularly [[gastric cancer]] and [[colorectal cancer]]. Apatinib works by inhibiting angiogenesis, the process by which new blood vessels form from pre-existing vessels, which is crucial for tumor growth and metastasis.&lt;br /&gt;
&lt;br /&gt;
== Mechanism of Action ==&lt;br /&gt;
Apatinib exerts its effects by binding to the intracellular domain of [[VEGFR-2]], thereby blocking the downstream signaling pathways that promote endothelial cell proliferation and migration. This inhibition leads to reduced tumor vascularization and, consequently, tumor growth suppression.&lt;br /&gt;
&lt;br /&gt;
== Clinical Applications ==&lt;br /&gt;
Apatinib has been studied extensively in clinical trials for its efficacy in treating advanced [[gastric cancer]] and other malignancies. It is often considered for patients who have not responded to standard chemotherapy regimens. The drug has shown promise in improving progression-free survival and overall survival in certain patient populations.&lt;br /&gt;
&lt;br /&gt;
== Side Effects ==&lt;br /&gt;
Common side effects of apatinib include hypertension, proteinuria, hand-foot syndrome, and fatigue. These adverse effects are generally manageable with supportive care and dose adjustments.&lt;br /&gt;
&lt;br /&gt;
== Research and Development ==&lt;br /&gt;
Ongoing research is exploring the potential of apatinib in combination with other therapeutic agents, such as [[immunotherapy]] and [[chemotherapy]], to enhance its anticancer effects. Studies are also investigating its role in treating other types of cancer, including [[non-small cell lung cancer]] and [[breast cancer]].&lt;br /&gt;
&lt;br /&gt;
== Related Pages ==&lt;br /&gt;
* [[VEGFR-2]]&lt;br /&gt;
* [[Angiogenesis]]&lt;br /&gt;
* [[Gastric cancer]]&lt;br /&gt;
* [[Colorectal cancer]]&lt;br /&gt;
* [[Tyrosine kinase inhibitor]]&lt;br /&gt;
&lt;br /&gt;
== Gallery ==&lt;br /&gt;
[[File:Apatinib_structure.svg|thumb|right|Chemical structure of Apatinib]]&lt;br /&gt;
&lt;br /&gt;
[[Category:Antineoplastic drugs]]&lt;br /&gt;
[[Category:Tyrosine kinase inhibitors]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>